Spectris™ treatment is associated with significant time saved in the OVERTURE feasibility and open label extension (OLE) study

The OVERTURE study demonstrated that Spectris treatment significantly reduced the decline of scale points in ADCS-ADL, MMSE and WBV over 6 months compared to sham treatment. Evaluation of the OVERTURE RCT and OLE demonstrated significant time saved up to 18 months of treatment. These outcomes may be meaningful to Alzheimer's patients and their caregivers and are being further evaluated in the ongoing HOPE pivotal trial of Spectris in mild-moderate AD (NCT05637801).